Pfizer to invest $120M at Kalamazoo facility for COVID-19 antiviral treatment
COVID-19 Antiviral Treatment Creates Demand for $120 Million Investment
Pfizer Inc plans to spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Kalamazoo, Michigan plant. Demand for Paxlovid in increasing, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.
Gov. Gretchen Whitmer, who joined Pfizer for the Monday announcement, said the move will build on the state’s economic momentum.
“We are the epicenter of the auto industry and home to countless other breakthroughs in sciences as well as advanced manufacturing, chips, semiconductors and more,” she said. “And with this investment in Kalamazoo. we’re shoring up our supply chain and showing the world that Michigan is the place to be for companies who want to do big things and need the incredible workforce to accomplish those things.”
Pfizer made some of the first doses of the COVID-19 vaccine at its 1,300-acre facility in Portage, the company’s largest production site, which sits just south of Kalamazoo.
According to officials, Pfizer has manufactured more than 5.5 million packs of the antiviral therapy, Paxlovid, across 26 countries.
The investment at the Kalamazoo County site is expected to help meet the global demand for Paxlovid. The site is expected to be among the world’s largest producers of active pharmaceutical ingredient for the drug with the capacity to produce 1,200 metric tons annually, officials said Monday.
Pfizer also announced Monday it plans an additional investment to expand its modular aseptic processing sterile injectable pharmaceutical production site in Portage. Last year, the company broke ground on the $450 million, 400,000-square-foot production facility.